Comparison of the safety profiles for pirfenidone and nintedanib: a disproportionality analysis of the US food and drug administration adverse event reporting system

• Egile Nagusiak: Xiangyu Sun (Egilea), Huaguang Wang (Egilea), Xi Zhan (Egilea), Yuanyuan Yan (Egilea), Kun Chen (Egilea), Zhuoling An (Egilea), Hong Zhou (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2024-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease of unknown etiology. Pirfenidone (PFD) and nintedanib (NDN) were both conditionally recommended in the clinical practice guideline published in 2015. Safety and tolerability are related to the risk of t...